Skip to main content
. Author manuscript; available in PMC: 2024 Apr 1.
Published in final edited form as: Am J Transplant. 2023 Jan 19;23(4):559–564. doi: 10.1016/j.ajt.2022.12.019

Figure 2:

Figure 2:

Figure 2:

Kaplan-Meier survival curves demonstrating freedom from CLAD or Death in patients receiving early, preemptive treatment of DSA. a) Comparison of early treatment vs. no early treatment. b) Comparison of early treatment vs. Clinical AMR treatment. Note that the “no early treatment” group includes patients that were never treated for dnDSA and patients receiving treatment only in the setting of clinical AMR. CLAD: Chronic Lung Allograft Dysfunction; DSA: Donor Specific Antibody; AMR: Antibody-Mediated Rejection; dnDSA: de novo DSA